- Conditions
- Alcohol Use Disorder
- Interventions
- Placebo, Semaglutide
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 622 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 19
- States / cities
- Long Beach, California • Palo Alto, California • West Los Angeles, California + 15 more
Location Directory
Clinical trials in Orlando, Florida
This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1524
Shown on this page
12
Current sort
Recently updated
Location scope
Orlando, FL
Filters apply within this location only.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Showing 697–708 of 1,524 matching trials in Orlando, FL.
Indexed local directory records.
Stored official records
Open in full search- Conditions
- Isolated/Primary Dystonia That Affects More Than One Region of the Body
- Interventions
- Not listed
- Lead sponsor
- Vima Therapeutics
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Aliso Viejo, California + 25 more
- Conditions
- Gastroesophageal Adenocarcinoma, Melanoma, Muscle-Invasive Bladder Carcinoma, Non-small Cell Lung Cancer
- Interventions
- Poly ICLC, Signatera or Altera testing, Synthetic long peptide personalized cancer vaccine
- Drug · Device · Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 3
- States / cities
- Orlando, Florida • St Louis, Missouri • Columbus, Ohio
- Conditions
- Chronic Subdural Hematoma
- Interventions
- Not listed
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 18
- States / cities
- Coral Gables, Florida • Jacksonville, Florida • Miami, Florida + 13 more
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Bevacizumab, Durvalumab, Transarterial Radioembolization (TARE)
- Drug · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 21
- States / cities
- Aurora, Colorado • Gainesville, Florida • Orlando, Florida + 16 more
- Conditions
- Advanced Solid Tumor, Hepatocellular Carcinoma
- Interventions
- TORL-4-500
- Drug
- Lead sponsor
- TORL Biotherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Angeles, California + 5 more
- Conditions
- Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Prostate Adenocarcinoma, Small Cell Lung Cancer, Triple Negative Breast Cancer
- Interventions
- BL-B01D1
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 22
- States / cities
- Beverly Hills, California • Duarte, California • Orange, California + 17 more
- Conditions
- End Stage Kidney Disease
- Interventions
- CSL300, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 166
- States / cities
- Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more
- Conditions
- Urethral Stricture
- Interventions
- Optilume Urethral DCB
- Combination Product
- Lead sponsor
- Urotronic Inc.
- Industry
- Eligibility
- 22 Years to 65 Years · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Orlando, Florida • Tampa, Florida + 6 more
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
- Interventions
- Pharmacokinetic Study, Ulixertinib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more
- Conditions
- Influenza, Human
- Interventions
- Licensed Influenza Vaccine, mRNA Seasonal Flu vaccine
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 54,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 161
- States / cities
- Anniston, Alabama • Guntersville, Alabama • Glendale, Arizona + 128 more
- Conditions
- Cardiovascular, Dyslipidemias, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Hypercholesterolaemia, Hypertriglyceridemia, Lipid Disorder, Metabolic Disease, Mixed Hyperlipemia, Severe Hypertriglyceridemia (sHTG)
- Interventions
- CTX310
- Drug
- Lead sponsor
- CRISPR Therapeutics AG
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Hialeah, Florida • Jacksonville, Florida • Orlando, Florida + 5 more